SAN DIEGO(BUSINESS WIRE)May. 18, 2009 Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from ARIES-3, an open-label, single-arm, Phase III study evaluating the efficacy and safety of ambrisentan in patients with pulmonary hypertension (PH), which showed a mean 21-meter improvement from baseline in six-minute walk distance (6MWD) at 24 weeks. Ambrisentan is approved under the tradename LetairisÂ® (ambrisentan 5 mg and 10 mg tablets) as a once-daily treatment for pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with WHO functional class II or III symptoms to improve exercise capacity and delay clinical worsening. The ARIES-3 study included patients with PAH (WHO Group 1) as well as patients with pulmonary hypertension due to other etiologies (WHO Groups 3, 4 and 5). Data from this study were presented today at the 2009 American Thoracic Society (ATS) International Conference, taking place May 15-20 in San Diego.
â€śIn previous clinical trials, ambrisentan has been shown to improve exercise capacity and delay clinical worsening in WHO Group 1 PAH patients with WHO functional class II and III symptoms,â€ť said David Badesch, MD, Professor of Medicine and Clinical Director of the Pulmonary Hypertension Center at the University of Colorado Health Sciences Center and lead study author. â€śHowever, many patients seen in clinical practice have pulmonary hypertension associated with other diseases. ARIES-3 is important because it represents the first safety and efficacy data for ambrisentan in a more diverse PH patient population, including patients already on background therapy.â€ť
For more information:
Last updated on: 27/08/2010